Home › Kanser sa Suso › Missouri › Kansas City
Pag-aaral pangklinika para sa Kanser sa Suso sa Kansas City, MO
34 pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Kansas City (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Vanguard Study: Testing a New Way to Screen for Cancer
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Saint Luke's Hospital of Kansas City, Kansas City
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Nagre-recruitPhase 3
- University of Kansas Cancer Center, Westwood · 5 mi ang layo
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Nagre-recruitPhase 3
- HCA Midwest Division, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Kansas City Veterans Affairs Medical Center, Kansas City
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Nagre-recruitPhase 2
- Saint Luke's Cancer Institute, Kansas City
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Nagre-recruitPhase 1
- St. Lukes Hospital of Kansas City, Kansas City
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Nagre-recruitPhase 3
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Nagre-recruitPhase 3
- The University of Kansas Cancer Center, Westwood · 5 mi ang layo
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Nagre-recruitPhase 3
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Nagre-recruitPhase 3
- Clinical Trial Site, Kansas City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Nagre-recruitPhase 3
- Saint Luke's Cancer Institute, Kansas City
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Nagre-recruitPhase 1/2
- Saint Luke's Hospital of Kansas City, Kansas City
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Nagre-recruitPhase 3
- Saint Luke's Hospital of Kansas City, Kansas City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Nagre-recruitPhase 1
- Saint Luke's Cancer Institute, Kansas City
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Nagre-recruitPhase 2
- HCA Midwest Division, Kansas City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Nagre-recruitPhase 3
- HCA Midwest Health, Kansas City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Nagre-recruitPhase 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- at 1 pa
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- at 2 pa
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Nagre-recruitPhase 3
- University of Kansas Cancer Center - North, Kansas City
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Nagre-recruitPhase 2/3
- Saint Luke's Cancer Institute, Kansas City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- University of Kansas Medical Center (KUMC), Westwood · 5 mi ang layo
HER2-positive Breast Cancer Registry
Nagre-recruitObservasyonal na pag-aaral
- The University of Kansas Cancer Center, Westwood · 5 mi ang layo
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Saint Luke's Cancer Institute, Kansas City
Integrated Cancer Repository for Cancer Research
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- at 1 pa
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Nagre-recruitPhase 3
- Saint Luke's Cancer Institute, Kansas City
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Nagre-recruitPhase 3
- Saint Luke's Cancer Institute, Kansas City
- The University of Kansas Cancer Center, Westwood · 5 mi ang layo
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
Nagre-recruitPhase 2
- The University of Kansas Cancer Center - North, Kansas City
- KUCC - Briarcliff, Westwood · 5 mi ang layo
- KUCC - Olathe, Westwood · 5 mi ang layo
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Nagre-recruitPhase 3
- Saint Luke's Hospital of Kansas City, Kansas City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Nagre-recruitPhase 3
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · 2 mi ang layo
- at 1 pa
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Nagre-recruitPhase 1/2
- The University of Kansas Cancer Center, Westwood · 5 mi ang layo
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Nagre-recruitObservasyonal na pag-aaral
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- at 1 pa
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Nagre-recruitObservasyonal na pag-aaral
- Saint Luke's Hospital of Kansas City, Kansas City
- University of Kansas Cancer Center, Westwood · 5 mi ang layo
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Kansas City
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Nagre-recruitPhase 3
- Truman Medical Centers, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · 2 mi ang layo
- at 1 pa
Pag-aaral para sa Kanser sa Suso sa ibang lungsod
- New York City, NY136 pag-aaral
- Houston, TX126 pag-aaral
- Boston, MA112 pag-aaral
- Nashville, TN81 pag-aaral
- Los Angeles, CA73 pag-aaral
- Edison, NJ68 pag-aaral
- St. Louis, MO64 pag-aaral
- Queens, NY64 pag-aaral
- Durham, NC64 pag-aaral
- Chicago, IL59 pag-aaral
- Philadelphia, PA56 pag-aaral
- Dallas, TX55 pag-aaral
Iba pang pag-aaral sa Kansas City
- Non-Small Cell Lung Cancer31 pag-aaral
- Pagkabigo ng Puso25 pag-aaral
- Kanser (lahat ng uri)21 pag-aaral
- Kanser sa Baga19 pag-aaral
- Colorectal Cancer16 pag-aaral
- Metastatic Cancer15 pag-aaral
- Acute Myeloid Leukemia15 pag-aaral
- Kanser sa Prostate14 pag-aaral
- Kanser sa Ovary11 pag-aaral
- Obesity11 pag-aaral
- Type 2 Diabetes11 pag-aaral
- Sakit sa Puso at Ugat ng Dugo11 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.